期刊文献+

盐酸替罗非班对严重冠心病的疗效和安全性评价 被引量:3

原文传递
导出
摘要 目的探讨盐酸替罗非班对冠心病严重三支病变患者的疗效和安全性。方法56例无法行PTCA或冠脉旁路移植术(CABG)冠心病患者,在给予阿司匹林、氯吡格雷和低分子肝素的基础上加用盐酸替罗非班,观察其疗效和安全性。结果替罗非班与阿司匹林、氯吡格雷和低分子肝素合用可明显缓解严重冠脉三支病变患者的心绞痛症状,尤其是高敏C-反应蛋白〉9mg/ml的患者,而出血不良反应无显著增加。结论替罗非班为治疗严重冠心病患者有效、安全的药物。
出处 《中国医师杂志》 CAS 2007年第11期1565-1566,共2页 Journal of Chinese Physician
  • 相关文献

参考文献6

  • 1Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Eng J Med, 1992, 326 : 242 -250.
  • 2Crouch M A, Napi J M, Cheang K I. Glycoprotein Ⅱb/Ⅲa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome. Ann Pharmacother,2003 ,37 :860-875.
  • 3Montalescot G, Barragan P, Wittenberg O, et al. For the ADMIRAL In- vestigators. Platelet glycoprotein Ⅱb/Ⅲa inhibit with coronary stenting for acute myocardial infarction. N Eng J Med ,2001,344 :1895-1903.
  • 4Haverkate F,Thompson SG, Pyke SD, et al. Production of c-reactive protein and risk of coronary events in stable and unstable angina : European concerted action on thrombosis and disabilities angina pectoris study group. Lancet, 1997,349:462-466.
  • 5Cyrus T, Sung S, Zhao L,et al. Effect of low-dose asprin on vascular inflammation, plaque stability, and antherogenesis in low-density lipoprotein recptor deficient mice. Circulation,2002,106 : 1282-1287
  • 6顾晴,陈纪林,阮英茆.阿司匹林、氯吡格雷及合用对兔动脉粥样硬化病变进展的抑制作用[J].中国医学科学院学报,2005,27(1):87-91. 被引量:46

二级参考文献14

  • 1Cyrus T, Sung S, Zhao L, et al. Effect of low-dose aspirin on vascular inflammation, plaque stability, and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation,2002, 106(10): 1282-1287.
  • 2Samama CM, Bonnin P, Bonneau M, et al. Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig. Throm Haemost, 1992, 68(5):500-505.
  • 3Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med, 1999, 340(24):115-126.
  • 4Huo Y, Schober A, Forlow SB, et al. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nature Medicine, 2003, 9(1):61-67.
  • 5Torzewski J, Torzewski M, Bowyer DE, et al. C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arteroscler Throm Vase Biol, 1998,18:1386-1392.
  • 6Tataru MC, Heinrich J, Junker R, et al. C-reactive protein and the severity of atherosclerosic in myocardial infaetion patients with stable angina pertoris. Eur Heart J, 2000,21(12):1000.
  • 7Muir KW, Weir C J, Alwan W, et al. C-reactive protein and outcome after ischemic stroke. Stroke, 1999, 30(5):981-985.
  • 8Herbert JM, Dol F, Bernat A, et al. The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost, 1998, 80(3):512-518.
  • 9Cha JK, Jeong MH, Lee KM, et al. Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. J Thromb Thrombolysis, 2002, 14(2):145-150.
  • 10Kinkhardt U, Kirchmaier CM, Westrup D, et al. Ex vivoin vitro interation between aspirin, clopidogrel, and glycoprotein Ⅱ b/Ⅲa inhibitors abeiximab and SR 121566A.Clin Pharmacol Ther, 2000, 67(3):305-313.

共引文献45

同被引文献28

引证文献3

二级引证文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部